Aravive Reports Updated Results of Batiraxcept in the P-Ib Study for the Treatment of Clear Cell Renal Cell Carcinoma
Shots:
- The P-Ib study evaluates batiraxcept (15/20mg/kg) + cabozantinib (60mg, qd) in 26 patients with ccRCC. The company will initiate the P-II portion of the trial in 2022
- The results showed no dose-limiting toxicities, 92% remain on the study at a median follow-up of 4.9mos., 46% ORR & 6mos. PFS rate (79%) in the ITT population, best ORR (56% & 30%) in 15 & 20mg/kg, no patient had progressive disease, m-DOR not reached with 3mos. DoR (100%)
- Additionally, 25 were evaluable for baseline sAXL/GAS6, ORR (63%) & 6mos. PFS rate (77%) in biomarker high population, best ORR (75% & 43%) in 15 & 20mg/kg population, 6mos. PFS rate (91%) in 15mg/kg biomarker high group & m-DoR with 3mos. DOR (100%)
Ref: Globenewswire | Image: Aravive
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
